New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease

New Zealand Medical Journal

Volumn 123, Issue 1314, 2010, Pages 121-

  Schultz, Michael ^a   Gearry, Richard ^b,c   Walmsley, Russell ^d,e   Day, Andrew S ^b   Fraser, Alan ^e   Wyeth, John ^f   Barclay, Murray ^b   Clover, Geoff ^g   Whiteside, Cathryn ^h  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f WELLINGTON HOSPITAL   (New Zealand)

^g Otago District Health Board   (New Zealand)

^h Hutt Valley District Health Board   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CHICKENPOX VACCINE; CORTICOSTEROID; CYCLOSPORIN A; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WART VIRUS VACCINE;

ANUS DISEASE; ANUS FISTULA; BIOLOGICAL THERAPY; CANCER RISK; CHILL; CONFERENCE PAPER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ENTERIC FEEDING; ENTERITIS; FISTULA; FLU LIKE SYNDROME; GASTROENTEROLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MEDICAL SOCIETY; NEW ZEALAND; PRACTICE GUIDELINE; PROGNOSIS; REMISSION; SIDE EFFECT; SKIN IRRITATION; SMOKING CESSATION; TREATMENT DURATION; TREATMENT FAILURE; ULCERATIVE COLITIS; URTICARIA; VACCINATION;

EID: 77952344764     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis;16:112-124
2. Rahier, FJ, Ben-Horin S, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis 2009;3:47-91.
3. Ouyang Q, Tandon R, Goh KL, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-1782
4. Pache I, Rogler G, Felley C. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly 2009;139:278-287
5. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008:CD006893.
6. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004:CD003574.
7. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35.
8. Travis, SP, Stange EF, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62.
9. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:935-939 (Pubitemid 43374542)
10. Hoffmann JC, Preiss JC, Autschbach F, et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Z Gastroenterol 2008;46:1094-1146
11. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83; quiz 4, 84.
12. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49:183-190
13. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-667
14. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009;104:3042-3049